Hearing Rehabilitation for Cognitive Impairment

N/A

Recruiting

Led By Esther Oh, MD, PhD

Research Sponsored by Johns Hopkins University

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Diagnosis of probable Alzheimer's Disease or other related dementia according to the core clinical criteria outlined in the National Institute on Aging (NIA) and Alzheimer's Association Guidelines

Age 60 - 100 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up baseline and 1 month post-intervention (immediate group). 1 month post-baseline (delayed group)

Summary

This trial aims to develop and test a hearing rehabilitation program that will be delivered by a speech-language pathologist to individuals with cognitive impairment. The program is designed to be affordable and easily accessible.

Who is the study for?

This trial is for English-speaking individuals aged 60-100 with probable Alzheimer's or related dementia, who live at home and have stable medication dosing. They must have adult-onset hearing loss and a caregiver available to assist with the study.

What is being tested?

The HEARS-SLP program and device are being tested to see if they can help people with cognitive impairment by providing affordable hearing care through speech-language pathologists.

What are the potential side effects?

Since this trial involves a non-invasive intervention focused on hearing health care, side effects may be minimal but could include discomfort from using the HEARS-SLP device.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I have been diagnosed with Alzheimer's Disease or a similar type of dementia.

Select...

I am between 60 and 100 years old.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ baseline and 1 month post-intervention (immediate group). 1 month post-baseline (delayed group)

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~baseline and 1 month post-intervention (immediate group). 1 month post-baseline (delayed group)

This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline and 1 month post-intervention (immediate group). 1 month post-baseline (delayed group) for reporting.